Robert Michael Dudley - Net Worth and Insider Trading

Robert Michael Dudley Net Worth

The estimated net worth of Robert Michael Dudley is at least $1,754 dollars as of 2024-11-13. Robert Michael Dudley is the CEO of TransCode Therapeutics Inc and owns about 4,507 shares of TransCode Therapeutics Inc (RNAZ) stock worth over $1,754. Details can be seen in Robert Michael Dudley's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Robert Michael Dudley has not made any transactions after 2023-09-28 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Robert Michael Dudley

To

Robert Michael Dudley Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Robert Michael Dudley owns 1 companies in total, including TransCode Therapeutics Inc (RNAZ) .

Click here to see the complete history of Robert Michael Dudley’s form 4 insider trades.

Insider Ownership Summary of Robert Michael Dudley

Ticker Comapny Transaction Date Type of Owner
RNAZ TransCode Therapeutics Inc 2023-09-28 director & 10 percent owner & Chief Executive Officer

Robert Michael Dudley Latest Holdings Summary

Robert Michael Dudley currently owns a total of 1 stock. Robert Michael Dudley owns 4,507 shares of TransCode Therapeutics Inc (RNAZ) as of September 28, 2023, with a value of $1,754.

Latest Holdings of Robert Michael Dudley

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
RNAZ TransCode Therapeutics Inc 2023-09-28 4,507 0.39 1,754

Holding Weightings of Robert Michael Dudley


Robert Michael Dudley Form 4 Trading Tracker

According to the SEC Form 4 filings, Robert Michael Dudley has made a total of 6 transactions in TransCode Therapeutics Inc (RNAZ) over the past 5 years, including 6 buys and 0 sells. The most-recent trade in TransCode Therapeutics Inc is the acquisition of 2,450 shares on September 28, 2023, which cost Robert Michael Dudley around $49,980.

Insider Trading History of Robert Michael Dudley

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Robert Michael Dudley Trading Performance

GuruFocus tracks the stock performance after each of Robert Michael Dudley's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Robert Michael Dudley is -60.98%. GuruFocus also compares Robert Michael Dudley's trading performance to market benchmark return within the same time period. The performance of stocks bought by Robert Michael Dudley within 3 months outperforms 0 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Robert Michael Dudley's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Robert Michael Dudley

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 6 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -21.19 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -19.14 LIMIT LIMIT LIMIT LIMIT LIMIT

Robert Michael Dudley Ownership Network

Ownership Network List of Robert Michael Dudley

No Data

Ownership Network Relation of Robert Michael Dudley

Insider Network Chart

Robert Michael Dudley Owned Company Details

What does TransCode Therapeutics Inc do?

Who are the key executives at TransCode Therapeutics Inc?

Robert Michael Dudley is the director & 10 percent owner & Chief Executive Officer of TransCode Therapeutics Inc. Other key executives at TransCode Therapeutics Inc include director & VP & Chief Financial Officer Thomas A Fitzgerald , 10 percent owner Anna Moore , and 10 percent owner Zdravka Medarova .

TransCode Therapeutics Inc (RNAZ) Insider Trades Summary

Over the past 18 months, Robert Michael Dudley made 4 insider transaction in TransCode Therapeutics Inc (RNAZ) with a net purchase of 154,607. Other recent insider transactions involving TransCode Therapeutics Inc (RNAZ) include a net purchase of 49,350 shares made by Thomas A Fitzgerald ,

In summary, during the past 3 months, insiders sold 0 shares of TransCode Therapeutics Inc (RNAZ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TransCode Therapeutics Inc (RNAZ) were sold and 5,099 shares were bought by its insiders, resulting in a net purchase of 5,099 shares.

TransCode Therapeutics Inc (RNAZ)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

TransCode Therapeutics Inc Insider Transactions

No Available Data

Robert Michael Dudley Mailing Address

Above is the net worth, insider trading, and ownership report for Robert Michael Dudley. You might contact Robert Michael Dudley via mailing address: C/o Transcode Therapeutics, 6 Liberty Square #2382, Boston Ma 02109.